Exobiosphere, the world’s first contract research organization dedicated to drug discovery in space, has raised €2 million in a seed round to scale its orbital high-throughput screening platform. 

The round was led by Expansion Ventures, a €200M pan-European venture capital fund backing category-defining founders in aerospace and defence. Significant participation came from Expon Capital, a premier Luxembourg-based firm investing in transformative technologies with the potential to reshape entire industries. The round also attracted Space Data Inc., a cutting-edge Japanese company pioneering real-time digital twin technology for Earth and space systems.  

Exobiosphere, the world’s first contract research organization dedicated to drug discovery in space, has raised €2 million in a seed round to scale its orbital high-throughput screening platform. 

The round was led by Expansion Ventures, a €200M pan-European venture capital fund backing category-defining founders in aerospace and defence. Significant participation came from Expon Capital, a premier Luxembourg-based firm investing in transformative technologies with the potential to reshape entire industries. The round also attracted Space Data Inc., a cutting-edge Japanese company pioneering real-time digital twin technology for Earth and space systems.